GW PHARMA JUMPS ON EUROPEAN DEAL FOR CANNABIS DRUG

A A

GW Pharmaceuticals has agreed a deal for Spain's Almirall to market its pioneering cannabis-based medicine, Sativex, in European countries excluding the UK, sending its shares higher on Monday. GW Pharma said it would receive a signature fee of 12 million pounds, within total potential milestone payments of 46 million pounds, and that it would maintain a significant share of long-term product revenues.

Scotsman (http://business.scotsman.com/latest.cfm?id=2392172005)